Recent developments in conducting polymers: applications for electrochemistry

Scientists have categorized conductive polymers as materials having strongly reversible redox behavior and uncommon combined features of plastics and metal. Because of their multifunctional characteristics, e.g., simplistic synthesis, acceptable environmental stability, beneficial optical, electronic, and mechanical features, researchers have largely considered them for diverse applications. Therefore, their capability of catalyzing several electrode reactions has been introduced as one of their significant features. A thin layer of the conducting polymer deposited on the substrate electrode surface can augment the electrode process kinetics of several solution species. Such electrocatalytic procedures with modified conducting polymer electrodes can create beneficial utilization in diverse fields of applied electrochemistry. This review article explores typical recent applications of conductive polymers (2016–2020) as active electrode materials for energy storage applications, electrochemical sensing, and conversion fields such as electrochemical supercapacitors, lithium-ion batteries, fuel cells, and solar cells.

Scientists have categorized conductive polymers as materials having strongly reversible redox behavior and uncommon combined features of plastics and metal.     

Synthesis of poly(N-isopropylacrylamide) polymer crosslinked with an AIE-active azonaphthol for thermoreversible fluorescence

A fluorescent polymer was synthesized using N-isopropylacrylamide (NIPAM) crosslinked with a divinylazonaphthol monomer via radical emulsion polymerization. Because the crosslinked polymer contained an aggregation-induced emissive (AIE) azonaphthol-based crosslinker, a thermoreversible sol–gel transformation and gelation-induced reversible fluorescence alteration were successfully attained in an aqueous medium. Like typical PNIPAM, the size and transmittance of the polymer dramatically decreased near the lower critical solution temperature (LCST, 36 °C). Such gelation facilitated aggregation of the polymer chains, resulting in the close contact between azonaphthol groups producing fluorescence. The crosslinked polymer exhibited changes in dual properties: one is related to PNIPAM structural alteration, which corresponds to conventional swelling/shrinkage behavior; and the other is involved in the reversible fluorescence change in response to the swelling/shrinkage. Because the major backbone of the polymer was composed of NIPAM with an LCST at 36 °C, the resultant polymer is expected to have potential applications in biologically related fields.

A novel thermoresponsive polymer with AIE behavior is developed for reversible fluorescence switching using unusual AIE-active azonaphthol derivatives.     

MVP™ Micro Vascular Plug Systems for the Treatment of Pulmonary Arteriovenous Malformations

CardioVascular and Interventional Radiology - To describe our institutional experience with MVP™ micro vascular plug systems for the treatment of pulmonary arteriovenous malformations...     

Safety and Efficacy of Percutaneous Cryoablation for Small Hepatocellular Carcinomas Adjacent to the Heart

PurposeThis study evaluated the safety and efficacy of percutaneous cryoablation for treatment of the left subdiaphragmatic small hepatocellular carcinomas (HCCs) adjacent to the heart.Materials and MethodsBetween September 2013 and March 2018, 189 consecutive patients underwent cryoablation for small HCCs (≤3 cm); 70 patients (mean: 61.3 ± 10.6 years of age; range: 40–82 years) with left hepatic tumors (22 juxtacardiac and 48 nonjuxtacardiac tumors) were retrospectively analyzed. Patients were divided into juxtacardiac and nonjuxtacardiac tumor groups (tumor margins: ≤10 mm and >10 mm, respectively, from the heart border). The rates of technical success, complete ablation, complications, and local tumor recurrence (LTR) were evaluated.ResultsNo significant intergroup differences were observed in the mean diameter of the tumor (17.9 ± 5.5 mm vs. 17.5 mm ± 5.2, respectively; P = 0.781) and of the ablation zone (41.3 ± 4.2 mm vs. 43.5 ± 5.8 mm, respectively; P = 0.115). Technical success was achieved in all patients. No procedure-related major complications occurred in either group. The median follow-up period was 15 months (range: 3.1–49.6 months). No statistically significant intergroup differences were observed in the rates of complete ablation (90.9% vs. 93.8%, respectively; P = 0.646) and LTR (20% vs. 15.6%, respectively; P = 0.725).ConclusionsCryoablation is a safe treatment modality for patients with juxtacardiac small HCCs, without an increased risk of cardiac complications compared to treatment of HCCs that are nonjuxtacardiac, and with comparable efficacy.     

Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti‐epidermal Growth Factor Receptor Antibody

GC1118 is an anti‐epidermal growth factor receptor (EGFR) monoclonal antibody that is currently under clinical development. In this study, the pharmacokinetics (PK) of GC1118 were modelled in monkeys to predict human PK and receptor occupancy (RO) profiles. The serum concentrations of GC1118 and its comparator (cetuximab) were assessed in monkeys with a non‐compartmental analysis and a target‐mediated drug disposition (TMDD) model after intravenous infusion (3–25 mg/kg) of these drugs. The scaling exponent of the EGFR synthesis rate was determined using a sensitivity analysis. The human cetuximab exposures were simulated by applying different exponents (0.7–1.0) for the EGFR synthesis rate in the allometric monkey PK model. Simulated C_max and area under the curve values therein were compared with those previously reported in the literature to find the best exponent for the EGFR synthesis rate in human beings. The TMDD model appropriately described the monkey PK profile, which showed a decrease in clearance (CL; 1.2–0.4 ml/hr/kg) as the dose increased. The exponents for CL (0.75) and volume of distribution (Vd; 1.0) were used for the allometric scaling to predict human PK. The allometric coefficient for the EGFR synthesis rate chosen by the sensitivity analysis was 0.85, and the RO profiles that could not be measured experimentally were estimated based on the predicted concentrations of the total target and the drug–target complex. Our monkey TMDD model successfully predicts human PK and RO profiles of GC1118 and can be used to determine the appropriate dose for a first‐in‐human study investigating this drug.